Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer

Abstract

This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).

Management of Ovarian Cancer in 14th Gestational Week of Pregnancy by Robotic Approach with Preservation of the Fetus

“…The use of carboplatin plus paclitaxel has been suggested for the chemotherapeutic treatment for epithelial ovarian cancer in non-pregnant women [15,16]. However, it raises concerns about the safety of taxanes administration during pregnancy.…”

Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management

“…The National Comprehensive Cancer Network guidelines recommend similar management, and the same regimens be used for EOC, FTC, and PPC 44. In fact, compared with the older clinical trials in ovarian cancer, most current and more recent ovarian cancer clinical trials have included patients with FTC and PPC, although they are considered distinct clinical entities 45–55. Since the current evidence points toward a common pathogenesis for ovarian cancer, FTC, and PPC, similar treatment of these cancers is likely to be the most appropriate management of all these tumors.…”

Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro

“…It usually remains asymptomatic until the tumor grows large enough to interfere with the function of other pelvic or abdominal organs. Although the clinical treatment of ovarian cancer by surgery in combination with chemotherapy and radiotherapy is effective, no significant milestones have been achieved in improving patients’ overall survival and quality of life 1. This could perhaps be attributed to the advancement of disease.…”

“…This could perhaps be attributed to the advancement of disease. Approximately 75%–80% of patients are diagnosed late and the 5-year survival rate is <30% 1,2. In recent years, gene immunotherapy has provided an important new direction in the treatment of cancer patients 3,4.…”